ArticleFrontiers in immunology2025
Identification and validation of paraptosis-related biomarkers in recurrent miscarriage.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent miscarriage (RM) is a pregnancy complication with growing evidence suggesting a role for paraptosis in its pathogenesis, though the underlying mechanisms remain unclear. This study investigated paraptosis-related genes (PRGs) as potential therapeutic targets. Methods: Transcriptome data for RM were obtained from public databases, while PRGs were sourced from existing literature. Biomarkers were identified through the intersection of differential expression analysis, weighted gene co-expression network analysis, machine learning algorithms and expression validation, followed by the construction and validation of a nomogram. Molecular mechanisms of the biomarkers were further explored through immune infiltration, enrichment analysis, and the construction of regulatory networks. Single-cell RNA sequencing (scRNA-seq) was performed for deeper insights into RM. Results: PCNPP3 and ELOA were selected as biomarkers related to paraptosis. A predictive nomogram was developed with strong accuracy. Enrichment analysis revealed that both PCNPP3 and ELOA were associated with E2F targets and the G2M checkpoint. In immune infiltration analysis, PCNPP3 exhibited a significant positive correlation with smooth muscle cells, while ELOA was notably associated with myocytes. Regulatory network analysis suggested that NEAT1 and NPPA-AS1 might modulate ELOA expression Conclusion: This study identified PCNPP3 and ELOA as biomarkers of RM and provides comprehensive insights into their molecular mechanisms, offering valuable perspectives for future RM research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.